# FDA warning letter names retatrutide and tirzepatide products

> FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.

- Evidence object: `story:fda-gram-peptides-warning-letter:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-31
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-gram-peptides-warning-letter/
- JSON record: https://peptidescanner.com/evidence/v1/objects/fda-gram-peptides-warning-letter-v1.json
- Content SHA-256: `f65f40c95e5f08deebc2a456f0d77a442f4667bf34c67355978c5f3cfeb473b2`

## Claims and source pins

### Headline

FDA warning letter names retatrutide and tirzepatide products ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

### Summary

FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide. ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

### Paragraph 1

The cited FDA warning letter identifies products marketed with retatrutide and tirzepatide and records the agency's stated regulatory findings concerning the recipient. ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

### Paragraph 2

A warning letter records FDA's position and requested response at the time it was issued. This update does not generalize those findings to unrelated products or report a later resolution. ([`fda-gram-peptides-warning-letter-2026`](#source-fda-gram-peptides-warning-letter-2026))

## Sources

<a id="source-fda-gram-peptides-warning-letter-2026"></a>
- **FDA warning letter to Gram Peptides** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026) (`fda-gram-peptides-warning-letter-2026`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "FDA warning letter names retatrutide and tirzepatide products." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/objects/fda-gram-peptides-warning-letter-v1.json SHA-256: f65f40c95e5f08deebc2a456f0d77a442f4667bf34c67355978c5f3cfeb473b2.